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http://dx.doi.org/10.1016/j.jmii.2012Background/Purpose: Mutations in rpsL and rrs genes are associated with resistance to strep-
tomycin in tuberculosis, but important geographical variation exists in these mutations. The
goal of this study was to characterize these mutations in isolates of streptomycin-resistant
mycobacteria originating from southeast Mexico.
Methods: Mycobacteria were isolated from patients with suspected drug-resistant tubercu-
losis. Susceptibility tests were carried out using the fluorometric method, and rrs and rpsL
DNA sequencing was performed by capillary electrophoresis.
Results: Some 136 drug-resistant isolates were recovered, of which 91(67%) exhibited resis-
tance to streptomycin. Mutations in rpsL were observed in 18 isolates (19%) in codons 43
(A/G, K/R, n Z 12) and 88 (A/G, K/R, n Z 4; A/C, K/Q, n Z 2). Mutations in rrs were
observed in 26 isolates (28%). These were at nucleotides 513 (A/C, n Z 8) and 516 (C/T,
n Z 6), and six novel mutations at nucleotides 483 (A/T, n Z 2), 485 (A/G, n Z 2), 496
(G/A, n Z 2), 795 (C/T, n Z 6), 870 (C/T, n Z 3), and 907 (A/C, n Z 3), with some
isolates showing more than one mutation. Finally, 47 (52%) of the isolates showed no mutation.
Conclusion: The variety and presence or absence of the mutations found suggest the circula-
tion of an important diversity of strains and the existence of additional mechanisms contrib-
uting to streptomycin resistance in the region.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Salud Pu´blica, Universidad Veracruzana, Av. Luis Castelazo Ayala s/n, A.P. 57. Col. Industrial Animas,
com (R. Zenteno-Cuevas).
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DNA solution was then stored at e20 C until use.Tuberculosis (TB) is a major cause of illness and death
worldwide. In 2009, the World Health Organization (WHO)
estimated that a third of the global population was infected
and reported an incidence of 9.4 million cases and
mortality of 1.68 million people.1
Most of the current drugs for treatment of TB have been
in use for over half a century. This, in combination with
poor management, has made it possible for strains to
develop resistance to one or all of the anti-tuberculosis
drugs. The fourth global report on anti-tuberculosis drug
resistance estimated that 20% of new TB cases were resis-
tant to one antibiotic (TB-DR), 5.3% were multi-drug-
resistant (TB-MDR) and 11% were resistant to strepto-
mycin (Sþ).2
Streptomycin, an aminoglycoside discovered in 1943,
was the first antibiotic with proven specificity against TB,
and it has been used in the treatment of pulmonary TB for
more than 65 years. It functions by inhibiting protein
synthesis by mycobacteria in extracellular form, specifi-
cally binding to the 12S subunit protein and 16S rRNA.
Resistance to streptomycin is mainly associated with two
genes: rpsL and rrs. The rpsL gene encodes the 12S subunit
protein, with mutations at codons 43 (A/G, Lys/Arg, Thr)
and 88 (A/G/C, Lys/Gln, Arg, Thr) predominant. The rrs
gene encodes 16S rRNA and its most frequent mutations are
in loop 530 and region 912.3e12
Despite progress in identification of rpsL and rrs muta-
tions in Sþ tuberculosis isolates, these genes have been
poorly studied and significant geographical diversity has
been described for the relevant mutations. The aim of this
study was therefore to determine the type and frequency
of rpsL and rrs mutations among Sþ mycobacteria isolates
from southeast Mexico.
Materials and methods
Clinical sample collection, isolation, and drug
susceptibility
Sputum samples were collected from individuals with sus-
pected DR-TB by the Public Health Laboratory of the State
of Veracruz, Mexico from 2007 to 2010. Decontamination
was carried out using N-acetyl-L-cysteineeNaOH and
primary mycobacterial isolation involved development on
Lo¨wensteineJensen medium. Susceptibility testing was
performed in duplicate using the fluorometric method
(BACTEC MGIT 960, Becton-Dickinson, Sparks, MD, USA) for
the drugs streptomycin (S), isoniazid, rifampin, etham-
butol, and pyrazinamide. Isolation of bacilli and resistance
assays were conducted at the biosecurity level III facilities
of the Public Health Laboratory of Veracruz.
DNA purification and amplification of rpsL and rrs
TheDNA of Sþ clinical isolates was extracted fromone loop of
culturedmycobacteriaaccording toVanSoolingenetal.13DNA
was resuspended in nuclease-free water and the concentra-
tion was determined by spectrophotometry using a Nanodrop100 instrument (ThermoScientific, Wilmington, DE, USA). The
A fragment of 272 bp of the gene rpsL, including codons
43 and 88, was obtained by PCR using the primers STR52R
(50-GTC AAG ACC GCG GCT CTG AA-30) and STR34F (30-TTC
TTG ACA CCC TGC GTA TC-50).14 Considering the most
common mutations (491, 513, 516 and 905), a 552-bp
fragment of the rrs gene was amplified using the primers
PR13F (50-AAA CCT CTT TCA CCA TCG AC-30) and PR30R (30-
CAG GTA AGG TTC TTC GCG TTG-5).15
The PCR reaction mix consisted of 10 mM Tris (pH 8),
1.5 mM MgCl2, 0.2 mM of each dNTP, 10 mM forward and
reverse primers, 1.25 U of Taq polymerase (Promega, Madi-
son, WI, USA), 5% glycerol, and 100 ng of DNA template and
was topped up with nuclease-free water to a final volume of
25 mL. Amplification was performed in a Veriti thermocycler
(Applied Biosystems, Foster City, CA, USA) according to the
following conditions: 95 C for 3 minutes, 35 cycles of 95 C
for 40 seconds, 57 C for 30 seconds and 72 C for 1 minute,
and a final extension step at 72 C for 3 minutes.
Products were separated electrophoretically on a 1.5%
agarose gel and were further purified using Amicon Ultra
centrifugal filters (Millipore, Carrigtwohill, Ireland). The final
concentration was determined by electrophoresis using
a Mass Ruler Low-Range DNA Ladder (Fermentas, Hanover,
MD, USA).
Sequencing of rrs and rpsL from mycobacterial
isolates
Sequencing reactions were performed in both forward and
reverse directions using a Big Dye Terminator Cycle
Sequencing Kit V3.1 (6 mL; Applied Biosystems), 3.2 pM
forward and reverse primers and 20 ng of purified PCR
product in a final volume of 20 mL. Amplification conditions
comprised 25 cycles of 95 C for 30 seconds, 50 C for 15
seconds and 60 C for 4 minutes.
Products were purified using a ZR DNA sequencing clean-
up kit (Zymo Research, Orange, CA, USA), resuspended in
Hi-Di formamide (Applied Biosystems), heated to 95 C for 5
minutes, cooled on ice, and finally loaded into a 96-well
MicroAmp reaction plate (Applied Biosystems).
Sequencing of DNA products was carried out by capillary
electrophoresis on a Genetic Analyzer 3500 system (Applied
Biosystems). Fluorescence spectra were analyzed using
Data Collection V1.01 software (Applied Biosystems).
Sequences were analyzed and mutations were identified
using the Sequencing Analysis V5.4 and SeqScape V2.7
programs (Applied Biosystems), respectively. Wild-type rrs
and rpsL genes from Mycobacterium tuberculosis H37Rv
(GenBank accesion number NC_00962, regions 1471846-
1473382 and 781560-781934) were used as reference
sequences. It is important to highlight that sequences were
analyzed only if they presented quality values for individual
mutations and a sample score greater than 20, thereby
ensuring that the base assignment error was <1%.
Results
From 2007 to 2010, 136 M. tuberculosis isolates were
collected. Resistance to isoniazid was identified in 113
32 B. Cuevas-Co´rdoba et al.individuals (83%), resistance to rifampin in 95 (70%), resis-
tance to ethambutol in 73 (54%), and resistance to pyr-
azinamide in 51 (38%). MDR was found in 66% of the isolates
and 23% were resistant to all the drugs tested. The average
age of the individuals was 45 years, 65% were men, and
diabetes was the most frequent co-morbidity, found in 29%
of the cases.
Resistance to streptomycin (Sþ) was found in 91 (67%)
individuals, of whom 55 (60%) were male. The mean age
was 45 (15) years. We observed that 73 (80%) of the
patients had been previously treated, while 18 (20%) were
new cases. Only one patient (1%) was infected with HIV, six
(6%) suffered from malnutrition, 26 (29%) had diabetes, and
10 (11%) suffered from alcoholism.
We found that 80 individuals (88%) showed resistance to
isoniazid, 66 (72%) to rifampin, 50 (55%) to ethambutol, and
40 (44%) to pyrazinamide. MDR was found in 65 (71%),
resistance to all the first-line drugs was observed in 32
(35%), and 6 individuals (6%) were mono-resistant to S.Identification of rpsL and rrs mutations in SD
isolates
For the 91 Sþ isolates, the same number of fragments of
rpsL (272 bp) and rrs (552 bp) were sequenced in both
directions. For rpsL, three mutations were observed in 18
(19%) isolates. The most common mutation was at codon 43
(A/G, K/R), found in 12 (13%) isolates, followed by
mutations at codon 88 (A/G, K/R; and A/C, K/Q) in four
(4%) and two (2%) isolates, respectively (Table 1).Table 1 Mutations in rpsL and rrs in 91 streptomycin-
resistant isolates from southeast Mexico
Nucleotide
(codon)
Polymorphism Amino
acid
Isolates, n (%)
rpsL gene
128 (43) A/G K/R 12 (13)
263 (88) A/G K/R 4 (4)
262 (88) A/C K/Q 2 (2)
Total 18 (19)
No mutations 73 (80)
rrs gene
483 A/Ta d 2 (2.2)
485 A/Ga d 2 (2.2)
496 G/Aa d 2 (2.2)
513 A/C d 8 (8.8)
516 C/T d 6 (6.6)
795 C/Ta d 6 (6.6)
870 C/Ta d 3 (3.3)
907 A/Ca d 3 (3.3)
Total 26 (28)b
No mutations 65 (71)
Total isolates
without
mutations
47 (52)
a Novel mutations.
b Six isolates showed more than one mutation.In the rrs fragments analyzed, eight different mutations
were identified in 26 (28%) isolates. The most frequent
mutations were at nucleotides 513 (A/C), found in eight
(9%) isolates, and 516 (C/T), found in six isolates (7%). In
addition, six previously unreported mutations were found.
These were at nucleotides 483 (A/T), 485 (A/ G) and 496
(G/A) in two isolates each, at nucleotide 795 (C/T) in six
isolates, and at nucleotides 870 (C/T) and 907 (A/C) in
three isolates each. (Table1). Six isolates showed more than
one mutation: one had three at nucleotides 483, 485 and
516, two isolates had the same mutations at nucleotides
795 and 870, and three isolates had the same mutations at
nucleotides 795 and 907.
All mutations were mutually exclusive between the
genes; isolates with rpsL mutations showed no rrs muta-
tions and vice versa. Of the Sþ isolates, 81% had no rpsL
mutations, while 72% had no rrsmutations. Finally, 47 (53%)
isolates showed no mutations in the gene fragments
sequenced.Discussion
The incidence of TB in Mexico is close to 14 cases per
100,000 habitants, with an annual estimate approaching
17,000. According to the Pan-American Health Organiza-
tion, Mexico is one of the countries with the highest inci-
dences of TB, DR-, and MDR-TB in Central and North
America.16
The isolates analyzed here were collected in Veracruz;
this state is the source of 10% of the TB and 35% of the DR-
TB cases reported nationally every year, and has one of the
highest populations of patients with MDR-TB. Veracruz
state is therefore considered one of the most important
contributors to DR-TB in Mexico.17
To the best of our knowledge, this study involves one of
the largest collections of DR-TB isolates from Mexico. Of
the 136 isolates, 66% were MDR, 23% presented resistance
to all the drugs analyzed, and 67% (91) were Sþ. This
resistance was observed in 20% of non-treated and 80% of
previously treated patients.
According to the last Mexican survey published on TB-
DR, 99 (21%) of 461 isolates analyzed had resistance to at
least one of the first-line drugs and 34 (7%) were TB-MDR. Of
the isolates analyzed, 73 (16%) were Sþ, of which 40 (54%)
were from non-treated and 31 (42%) from previously
treated patients.18 Although the population analyzed in our
study and that in the national survey are not comparable,
resistance to streptomycin in both cases was greater than
the global incidence of 11% reported by WHO.2 Publication
of results from the national survey of TB-DR conducted in
2010 should help in evaluating the actual extent of resis-
tance to streptomycin in Mexico.19
For rpsL, the most common mutations were observed at
codons 43 and 88, and these are frequently described in
several geographical regions.7,9e12,20 In a previous study in
Mexico, the mutation at codon 43 was observed in six Sþ
isolates from the north of the country.6 However, our results
represent the first description of mutations at codon 88.
For rrs, eight different mutations were found. Those at
codons 513 and 516 are the most frequently observed in Sþ
isolates from different geographical regions,9e12 including
rrs and rpsL mutations 33Mexico, where the 516 mutation was found in a single
isolate6; our report is the first to describe the mutation at
codon 513. However, mutations described as common at
nucleotides 426 and 4919,20 were absent in our isolates.
Finally, we could find no reports relating to the six novel
mutations found in rrs, making this their first description.
Mutations in rpsL and rrS are associated with resistance
to S.12,21 The main limitation of our study is the inability to
demonstrate a direct relationship between the six new rrS
mutations and resistance to S. However, it is important to
note that rrS mutations have been associated with resis-
tance to aminoglycosides.22e24 Some 50% of the isolates
harboring these newly identified mutations were also
resistant to all the first-line drugs, so they could be
extensively drug-resistant (XDR)-TB, which has already
been described in Mexico.25 In fact, we are starting an
analysis of the participation of these mutations in S resis-
tance and the potential XDR behavior of these isolates.
No mutations were found in 47 (52%) of the Sþ isolates
analyzed. We analyzed so-called hot spot-regions of the rrS
and rpsL genes, but it is possible that resistant isolates have
mutations in other regions of these genes. Moreover, such
a lack of mutations is frequently described, with important
variations in different geographical regions; for example,
an absence of mutations was observed in 22%6 and 44%9 in
Sþ isolates from northern Mexico and Brazil. In Portugal,
Poland, and Spain, the percentage of non-mutation isolates
was 33%26, 51%5 and 62%,12 respectively. Finally, the values
reported in Japan and China were 14%4 and 53%,8 respec-
tively. It was recently suggested that other mechanisms
could be involved in the generation of resistance to strep-
tomycin; these include mutations in the gidB gene10,27e29
and alterations in efflux pumps.9 A lack of mutations has
also been related to species of the Mycobaterium avium
complex, suggesting that this group has unique mechanisms
of resistance.30 All of these mechanisms should be sub-
jected to detailed evaluation to further understand the
processes governing streptomycin resistance in isolates
from southeast Mexico.
It has been argued that the variety and presence or
absence of rrs and rpsLmutations are the result of adopting
different treatment schemes by the health authorities and
of the design and duration of the study and collection
period for isolates.8 Furthermore, it was recently demon-
strated that the TB-DR genotypes circulating in the region
are important contributors to the variation of these muta-
tions.11,12 These characteristics were observed in the
present study and help to explain the variety identified.
The National Guide for TB patient Care in Mexico estab-
lished in 2003 states that streptomycin is to be adminis-
tered (1 g/day) for a period of 8 months only for patients
with a relapse or for whom primary treatment fails or is
neglected31; in addition, in the isolates analyzed we found
important genotype diversity among the TB-DR strains
circulating.32,33
The mechanism of streptomycin administration
described above also helps to explain the high levels of Sþ
isolates (67%) that also showed MDR (65%) and resistance to
all drugs (35%). In addition, it raises the possibility that the
18 individuals with first-time treatment and Sþ were
infected with tuberculosis isolates that had prior resistance
to drugs. This was confirmed by the fact that 72% of theseindividuals were MDR and all were also resistant to more
than one drug. Therefore, resistance to streptomycin could
be a potential surrogate diagnostic marker for secondary
resistance and MDR in new cases of tuberculosis in Mexico.
However, additional analysis is required to confirm this
possibility.
In conclusion, our findings reveal that only 48% of the Sþ
isolates featured mutations in rpsL and rrs genes. This may
negatively influence the development of a molecular test
for diagnosis of streptomycin resistance and suggests the
occurrence of additional mechanisms associated with
streptomycin resistance in isolates from the region.Acknowledgments
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